Earnings call transcript: Fortrea Q3 2026 results miss estimates, shares fall 11%

Fortrea’s Q3 2026 adjusted EPS of $0.28 missed the $0.63 consensus by 55.6%, while revenue of $691.5 million was 22.5% below the $892.33 million forecast; shares fell 11.07% to $23.02 in premarket trading. Adjusted EBITDA margin expanded 120bps year over year to 8.4%, free cash flow was $52.5 million, and management raised the midpoint of full-year revenue guidance to $2.6775 billion and adjusted EBITDA guidance to $214 million. Management expects Q4 revenue to slow sequentially, citing fewer working days, and reported a $558 million cumulative backlog adjustment that it said does not affect near- or medium-term revenue modeling.

Analysis

The headline-sized “miss” is not yet a clean signal: the cited $892 million quarterly revenue estimate appears inconsistent with Fortrea’s $2.665–$2.690 billion full-year guide. Verify estimate period, scope and data-vendor mapping before anchoring on the stated 22.5% shortfall. If the comparison is valid, the market is discounting conversion reliability, not simply weaker demand.

Economically, slower pass-through conversion can depress reported revenue more than fee economics, while mix and cost actions lift EBITDA margin. That makes margin progress real but not proof of durable operating leverage: the test is service-fee growth, utilization and repeatable conversion. The backlog reset is not a near-term revenue cut by management’s account, but it reduces confidence in the long-duration opportunity pool and makes headline book-to-bill less informative. A 1.12 ratio cannot offset weak realized conversion until awards become revenue.

Near term (days to weeks), expect elevated volatility and skepticism toward guidance. Over 1–3 months, watch bookings quality, cancellations/amendments and Q4 service-fee conversion; fewer working days explain some sequential deceleration, but do not explain a persistent bookings-to-revenue gap. Over 6–18 months, successful integration of Early Phase Services and technology-led productivity could improve mix and capture work from CRO competitors such as IQVIA and Medpace, but management has not yet established a 2027 growth trajectory. Contrarian point: the selloff may overstate deterioration if the estimate is mis-scoped and pass-through explains much of the revenue weakness; it is not yet a confirmed bargain given the backlog reset and no 2027 guide.

Key Decisions for Investors

• Do not trade the reported revenue-surprise percentage until consensus scope is verified against company filings and the original estimate source; treat this as an immediate data-quality alert.
• Avoid adding to FTRE into the first post-earnings session. Reassess after the opening range and await evidence that bookings convert into service-fee revenue; a sustained break below the $23.02 premarket indication would strengthen the tactical downside case, while recovery above the opening range weakens it.
• For the next 1–3 months, keep FTRE at neutral/underweight versus CRO exposure until cancellations, net awards and conversion support the growth narrative. Falsify this cautious stance if service-fee revenue accelerates while EBITDA margin holds or expands without another backlog reset.
• Monitor Early Phase Services for bookings and evidence of EBITDA profitability in 2027, plus leverage and free-cash-flow progress. Failure to convert the acquired capability into awards, or renewed deterioration in conversion, would undermine the longer-term margin-expansion thesis.